Bavarian stock price drops despite guidance upgrade and EU monkeypox vaccine order

Looking for an explanation for why Bavarian’s newest vaccine contract hasn’t been met with market enthusiasm, one Sydbank analyst points to a generally rainy trading day.

Photo: Bavarian Nordic / PR

The European Union had already indicated interest in a shared purchase of vaccine doses for monkeypox, so Tuesday’s news that the EU has signed a contract shouldn’t have come as a big surprise, according to Senior Equity Analyst at Sydbank Søren Løntoft Hansen.

In extension, the somewhat expected subsequent guidance upgrade from the biotech company hasn’t been able to offset the day’s downswing on the Copenhagen C25 index on which Bavarian is listed, as the firm has taken a dive with the rest of the market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs